Compare Amphastar Pharmaceuticals Inc (AMPH) vs Xpeng Inc - ADR (XPEV) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

XPEV trades at $13.03, up 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $73.9B but a net loss of $2.3B, continuing negative profitability trends. Recent news highlights include Robotaxi testing and European market expansion, while analyst consensus remains 64.7% buy despite cash flow challenges.

Outlook is mixed: growth in autonomous driving and international markets offers upside, but persistent losses and competitive pressures pose significant risks. Investors should weigh innovation potential against financial sustainability in the volatile EV sector.